MedTrace Logo

Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study

NCT04888793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2021-11-16

No results posted yet for this study

Summary

Despite COVID-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide. Fortunately, SARSCoV2 vaccines have been developed at an unprecedented pace. While the vaccination programs are still ongoing, early reports on efficacy are mainly centered on healthy population. In Chile most people have received the inactivated Coronavac vaccine. Data on the immune response after vaccination in immunocompromised patients is lacking. Therefore, this study aims to evaluate the immune response after Coronavac vaccine in 5 cohorts of immunocompromised patients and healthy controls. We will include patients with cancer, HIV, solid organ transplant and patients receiving immunomodulatory agents for rheumatic diseases.

Conditions

  • Covid19
  • COVID-19 Vaccines

Interventions

DIAGNOSTIC_TEST

Serologic immune response evaluation

Detection of total and neutralizing antibodies against SARS-CoV-2

Sponsors & Collaborators

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Elvira Balcells, MD · Pontificia Universidad Catolica de Chile

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-12
Primary Completion
2021-09-01
Completion
2021-11-01

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04888793 on ClinicalTrials.gov